Clotting cascade initiating apparatus and methods of use and methods of closing wounds

• US 8,652,169 B2
• Filed: 03/28/2013
• Issued: 02/18/2014
• Est. Priority Date: 12/16/1997
• Status: Expired due to Fees

• Current Assignee: Closys Corporation
• Original Assignee: Closys Corporation
• Inventors: Nowakowski, Karol L
• Primary Examiner(s): Dornbusch, Dianne
• Application Number:
  US13/852,094
• Publication Number:
  US 20130211449A1
• Time in Patent Office: 327 Days
• Field of Search: 606/213, 606/214, 606/232, 424/424, 424/425, 424/423, 424/520, 424/529, 128/898
• US Class Current: 606/214
• CPC Class Codes: A61B 17/00491 Surgical glue applicators surgical adhesives A61L24/00; two-component delivery syringes A61M5/19
• CPC Class Codes: A61B 17/0057 Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect sutures A61B17/04; closing rectum or urethra near body surface A61F2/0009
• CPC Class Codes: A61B 2017/00637 for sealing trocar wounds through abdominal wall
• CPC Class Codes: A61B 2017/00641 for closing fistulae, e.g. anorectal fistulae
• CPC Class Codes: A61B 2017/0065 the implement being an adhesive
• CPC Class Codes: A61L 24/0005 Ingredients of undetermined constitution or reaction products thereof
• CPC Class Codes: A61M 2025/0681 Systems with catheter and outer tubing, e.g. sheath, sleeve or guide tube
• CPC Class Codes: A61M 25/0662 Guide tubes

Abstract

Wound closure methods and apparatuses are provided which utilize blood fluid by activating the clotting cascade of the blood fluid outside the body within a substantially enclosed sterile container then introducing coagulated blood to the wound site. Methods and apparatuses for providing ways of inhibiting anticoagulants and slowing fibrin clot degradation are also disclosed. Kits for practicing the invention singularly or in combination with and/or associated with preferred procedures are also disclosed.

Claims

1. A method of treating a wound on a blood vessel of a patient using an apparatus comprising:

collecting whole blood from the patient into a sterile containment chamber of the apparatus;

exposing the whole blood to a procoagulant in the containment chamber to generate autologous clotted blood;

transferring at least a portion of the autologous clotted blood through an opening of the apparatus placed proximate the wound to subcutaneously deliver the at least the portion of the autologous clotted blood proximate the wound.

2. The method of claim 1 wherein the collecting comprises collecting the whole blood from the wound on the blood vessel via the opening of the apparatus.

3. The method of claim 2 further comprising:

establishing fluid communication between the apparatus and the blood vessel via the opening; and

verifying the fluid communication.

4. The method of claim 3 wherein the verifying the fluid communication comprises collecting whole blood within a lumen distinct from the containment chamber.

5. The method of claim 4 wherein the verifying comprises visualization of at least a portion of the whole blood collected within the lumen.

6. The method of claim 1 wherein the procoagulant is predisposed within the apparatus.

7. The method of claim 1 wherein the procoagulant is predisposed within the containment chamber.

8. The method of claim 1 wherein the procoagulant comprises a porous matrix.

9. The method of claim 1 wherein the procoagulant comprises a porous matrix selected from the group consisting of cotton and diatomaceous earth.

10. The method of claim 1 wherein the procoagulant comprises glass.

11. The method of claim 1 wherein the procoagulant comprises a synthetic polymer.

12. The method of claim 11 wherein the synthetic polymer is selected from the group consisting of dacron, silicone, polyurethane, polycarbonate, polyethylene, polyvinylchloride, polypropylene, and nylon.

13. The method of claim 1 wherein the procoagulant comprises thrombin, collagen, fibrin, and fibrinogen.

14. The method of claim 1 wherein the procoagulant comprises heat.

15. The method of claim 1 wherein the procoagulant comprises aminocaproic acid.

16. The method of claim 1 wherein the whole blood contains an anticoagulant.

17. The method of claim 1 further comprising treating the whole blood with an anticoagulant inhibitor.

18. The method of claim 17 wherein the anticoagulant inhibitor is an agent capable of binding an anticoagulant.

19. The method of claim 18 wherein the anticoagulant inhibitor comprises diethylaminoethyl cellulose.

20. The method of claim 1 further comprising treating the whole blood with an anticlot inhibitor.